The etiology of adolescent idiopathic scoliosis (AIS), the most common form of scoliosis, is unclear. Several divergent hypotheses have been postulated to better define this etiology (reviewed in several articles [1] [2] [3] [4] [5] ). Genetics, growth hormone secretion, connective tissue structure, muscle structure, vestibular dysfunction, melatonin deficiency, and platelet abnormalities are major areas of research. 4 Adolescent idiopathic scoliosis affects mainly girls in number and severity, but despite the fact that several studies have suggested a genetic predisposition, the form of inheritance remains uncertain. 6 -9 The neuroendocrine hypothesis involving a melatonin deficiency as the source for AIS has generated a great interest. This hypothesis stems from the fact that experimental pinealectomy in chicken, and more recently in rats, maintained in a bipedal mode, produces a scoliosis 10 -13 that resembles in many aspects the human disease. Postpinealectomy treatments with melatonin, the major hormone of the pineal gland, prevents the formation of scoliosis in both animal models. 4, 10 However, the biologic relevance of melatonin in AIS is controversial because: 1) no significant decrease in circulating melatonin level has been observed in a majority of studies 14 -16 ; 2) experimental pinealectomy did not lead systematically to a scoliosis in all pinealectomized chicken [17] [18] [19] [20] ; and 3) melatonin injections in pinealectomized animals did not always prevent the formation of a scoliosis. 21 Taken together, these reports raised doubts regarding the role of melatonin in AIS etiopathogenesis. These considerations led us to look instead at the melatonin signal transduction pathway because a defect of melatonin signaling activity could generate effects similar to a melatonin deficiency. For the present study, cells isolated from patients with AIS and patients suffering from other type of spinal deformity were compared owing to the property of melatonin to inhibit the accumulation of cAMP-induced by forskolin in normal cells due to the coupling of melatonin receptors to inhibitory guanine nucleotide-binding (Gi) pro-teins. [22] [23] [24] [25] [26] The osteoblasts, the bone-forming cells, were selected to assess whether or not an alteration of melatonin signaling pathway occurs in AIS and accordingly to identify which component of the melatonin transduction machinery could be involved. The physiologic relevance of the osteoblasts as cellular model for this study is further supported by the fact that: 1) bone is a well known tissue responding to melatonin [27] [28] [29] ; and 2) a persistent osteopenia is often reported in patients with AIS.
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Methods
Study Design. The melatonin signal transduction pathway functionality was investigated in osteoblasts from a series of patients clinically well defined with AIS (n ϭ 41) and compared with a series of age-and gender-matched patients presenting another type of scoliosis (n ϭ 15), including congenital scoliosis (n ϭ 3) or none (n ϭ 2). An informed consent was obtained for each patient as approved by our Institutional Ethical Committee.
Clinical Characteristics of Patients With Adolescent Idiopathic Scoliosis and Control Patients.
The clinical characteristics of the examined AIS and control subjects are shown in Table 1 and Table 2 , respectively. All patients with AIS and control patients were previously examined by one of our orthopedic surgeons (B.P., H.L., C-H.R., G.G.). All the clinical variables indicated were obtained at the moment of the surgery. Hereditary links were established by asking the patients and their relatives about the presence or not of a spinal deformity affecting a family member.
Isolation of Human Osteoblasts. Osteoblasts were obtained intraoperatively from bone specimens originating from vertebrae in all cases (varying from T3 to L4 according to the surgical procedure performed) with the exception of case 41, where an iliac crest biopsy was performed on a patient with Duchenne muscular dystrophy (DMD) without a scoliosis (control patient). Bony fragments were mechanically reduced in smaller pieces with a bone cutter in sterile conditions and incubated at 37°C in 5% CO 2 in a 10-cm culture dish, in presence of Adenylyl Cyclase Activity Assay in Osteoblasts. The functionality of melatonin signaling was assessed by investigating the ability of Gi proteins to inhibit stimulated adenylyl cyclase activity in osteoblast cultures. Osteoblasts from patients with AIS and control patients were seeded in quadruplet on a 24-well plate (5 ϫ 10 4 cells/well) and incubated with the vehicle alone, dimethyl sulfoxide (DMSO, Sigma, Oakville, ON, Canada), or forskolin (10 Ϫ5 M, Sigma) to stimulate the cAMP formation. Inhibition curves of cAMP production were generated by adding melatonin to the forskolin-containing samples in concentrations ranging from 10 Ϫ11 M to 10 Ϫ5 M in a final volume of 1 mL of ␣-MEM media containing 0.2% bovine serum albumin (BSA; Sigma). After a 30-minute incubation at 37°C, the cells were lysed and the sample centrifuged at 4°C. The cAMP content was determined in 200 L aliquot of the supernatant using an enzyme immunoassay kit (AmershamPharmacia Biosciences, Mississauga, ON, Canada). All assays were performed in duplicate. The functionality of Gi proteins was assessed by investigating their ability to inhibit adenylyl cyclase activity in osteoblasts. To obtain inhibition curves of cAMP production, the nonhydrolysable analogue of GTP, Gpp(NH)p (guanilyl 5'-imidophosphate, Sigma), was added to the forskolin-containing samples in concentrations ranging from 10 Ϫ9 M to 10 Ϫ4 M. The cAMP content was determined as described above in similar assays with melatonin.
Determination of Human MT1 and MT2 Localization.
Receptor subtype localization and distribution were determined by immunohistochemistry (IHC) assays with antihuman MT1 and antihuman MT2 antibodies (1:200 dilution of primary antibodies; 1:100 dilution of anti rabbit immunoglobulin G (IgG) biotinylated secondary antibodies; 1:200 dilution of Streptavidin-FITC conjugate or Streptavidin-Phycoerythrine conjugate (BioSource Inc. Camarillo, CA) on methanol fixed human osteoblasts. Production and characterization of MT1 and MT2 antibodies were previously described elsewhere.
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Membrane Preparation, Solubilization, and Human MT2 Receptor Immunoprecipitation. Cells were grown to confluence in 10-cm tissue culture dishes, rinsed twice in icecold phosphate-buffered saline (PBS), and scraped off their plastic support in 2 mL of ice-cold buffer: 5 mmol/L Tris (pH 7.4), 2 mmol/L EDTA, and a protease inhibitor cocktail (2 tablets of Complete™/50 mL of buffer, Roche Diagnostic Corp. Indianapolis, IN), then homogenized with a Polytron for 5 seconds at 30,000 rpm. Lysate was centrifuged at 450 g for 5 minutes at 4°C, and supernatant (2 mL) was added on the top of 9 mL of 35% sucrose cushion in ultracentrifugation tubes (Beckman Instruments Inc. Palo Alto, CA). Plasma membrane fractions were sedimented by ultracentrifugation at 150,000 g for 90 minutes at 4°C and pellet membrane was resuspended in 1 mL of ice cold buffer: 50 mmol/L Tris (pH 7.4), 5 mmol/L MgCl 2 , 2 mmol/L EDTA, and a protease inhibitor cocktail, then incubated with or without melatonin (10 Ϫ7 M) for 1 hour at 25°C. Membranes were pelleted by centrifugation at 18,000 g for 20 minutes at 4°C. The pellet was washed with ice-cold buffer: 75 mmol/L Tris (pH 7.4), 12 mmol/L MgCl 2 , 2 mmol/L EDTA, and a protease inhibitor cocktail, and then resuspended in the same buffer containing 1% Triton X-100, and agitated overnight at 4°C. Nonsolubilized membrane proteins were removed by centrifugation at 18,000 g for 20 minutes at 4°C. Protein determination was made by the method of Bradford using BioRad protein assay reagents (BioRad, Mississauga, ON, Canada). The Triton X-100 concentration was adjusted to 0.2%, and human MT2 antibodies were added to a final dilution of 1:80. Extracts were incubated for 18 hours at 4°C with continuous gentle mixing. During the last 6 hours, 50 L of a 50% (v/v) Protein A-agarose suspension were added. After centrifugation for 1 minute at 5000 g, supernatants were decanted and the agarose beads washed 5 times with 1 mL of ice-cold buffer: 75 mmol/L Tris (pH 7.4), 12 mmol/L MgCl 2 , 2 mmol/L EDTA protease inhibitor cocktail, and 0,05% Triton X-100.
Identification of Gi Protein Coupled to the Human MT2
Receptor. Membranes (100 g protein) from first passage human osteoblasts were incubated with or without melatonin (10 Ϫ7 M) for 1 hour at 25°C. For ligand-stimulated samples, all subsequent steps were performed in the continued presence of ligand. Receptors were solubilized and precipitated with Statistical Analysis. Results from the cAMP accumulation assays are given as the mean (pmoles/10 5 cells) Ϯ SEM. A nonparametric test, the Sign test, was used to verify the significance between 2 means. Significance was defined as P Ͻ 0.05, and data were analyzed with StatView and Statistica softwares.
Results
Our results define for the first time a dysfunction of melatonin signaling in bone-forming cells of patients with AIS. Except from AIS osteoblasts, melatonin produced an inhibition of forskolin-stimulated adenylyl cyclase activity detectable by a reduction of cAMP levels of about 60% to 70% (Figures 1 and 2 ). In contrast, osteoblasts from patients with AIS showed a lack or a markedly reduced inhibition of forskolin-stimulated adenylyl cyclase activity by melatonin (Figures 1 and 2) . Interestingly, osteoblasts isolated from patients with AIS displayed 3 types of response in presence of varying concentrations of melatonin, which allowed a classification of patients with AIS into 3 groups using this functional assay (Figure 2 and Table 3 ). In the first group, addition of melatonin increased cAMP accumulation in treated osteoblasts, which contrasted with the normal inhibitory values obtained with control patients ( Figure  2 ) and those reported in the literature in many cell lines. In the second group, osteoblasts from patients with AIS did not respond to melatonin treatments even at the pharmacological dose (10 Ϫ7 M) or higher (10 Ϫ5 M). Finally, the third group showed only a weak response toward melatonin treatment, although at the physiologic dose (10 Ϫ9 M) no significant inhibition was measured. Basal and forskolin-induced cAMP values are reported for each patient with AIS and control patient in Table 4 .
Comparison of basal and induced cAMP levels revealed increased values for basal cAMP in groups 2 and 3, whereas values for forskolin-stimulated cAMP levels were especially elevated in groups 1 and 3 (Table 3) . Interestingly, analysis of cAMP levels in presence of a physiologic dose of melatonin (10 Ϫ9 M) revealed a significant increase for patients with AIS in group 1 and 2 when compared to those obtained in Group 3 and control patients with P values of 0.0023 and 0.0001, respectively (Table 3) . However, analysis of clinical variables present in each AIS group showed no significant association due to the limited number of patients in each group. 
Determination of Melatonin Receptors MT1 and MT2 Localization and Function
Immunohistochemistry assays with specific antibodies were performed to assess whether the dysfunction of melatonin signaling observed could be secondary to either a reduced level of melatonin receptors or to mutation affecting their functions. Comparison of individual melatonin receptor subtype allowed determining their respective localization in osteoblasts isolated from patients with AIS and control patients tested (Figure 3 ). So far, no significant variation was observed in the localization or distribution of MT1 and MT2 receptor by con- 
Analysis of Gi Proteins Functionality and Coupling to Melatonin Receptor Subtypes
In vitro assays with Gpp(NH)p reduced cAMP levels in osteoblasts from control patients in contrast to patients with AIS tested, which showed no inhibitory effect for a majority of patients with AIS. The distribution of single data points obtained from each patient is reported in Figure 4 . The values reported in Figure 4 were detected after the administration of 10 Ϫ7 M Gpp(NH)p, a GTP nonhydrolysable analogue. The results indicated that about 50% of patients with AIS and those suffering of congenital scoliosis did not show an inhibition of cAMP accumulation induced by forskolin in presence of increasing doses of Gpp(NH)p, which contrasted with the inhibitory curves generated with the osteoblasts from control patients (data not shown). Coimmunoprecipitation assays with MT1 and MT2 antibodies reacting with individual melatonin receptor subtype showed a predominant coupling of Gi 3 proteins with the MT2 receptor subtype in purified osteoblast membrane fractions treated or not with melatonin ( Figures 5 and 6 ). Interestingly, Western blot analysis with Gi 1-3 antibodies revealed the presence of 2 immunoreactive bands, 43 kDa and 60 kDa, corresponding to the unphosphorylated and phosphorylated form of individual Gi protein, respectively. Immunodetection assay with specific antibodies reacting with phosphoproteins were performed and confirmed the presence of at least 1 phosphoserine residue in 60 kDa Gi proteins (Figures 5-7) . Interestingly, similar assays with osteoblasts isolated from patients with AIS revealed distinct phosphorylation patterns with and without melatonin addition (Figures 5 and 6 ). Treatments of osteoblast cultures with kinase or phosphatase inhibitors revealed that phosphorylation of serine residues in Gi proteins is indirectly modulated by a tyrosine kinase because treatments with genistein or herbimycin, 2 tyrosine kinase inhibitors, abrogated the formation of Figure 3 . Detection of MT1 and MT2 melatonin receptors in human osteoblasts. Panels illustrate representative immunohist o c h e m i s t r y e x p e r i m e n t s performed with MT1 receptor antibodies (upper panels) and MT2 receptor antibodies (lower panels) on primary human osteoblast cultures prepared from patients with AIS (AIS1-2) and compared to a control patient. Note that in both cases, no significant change was observed between patients analyzed. Magnification ϫ63 using a Zeiss LSM 510 confocal microscope.
the 60 kDa Gi proteins in control cells (Figure 7) . However, these inhibitors did not suppress Gi protein phosphorylation in osteoblasts isolated from patients with AIS ( Figures 5 and 6 ). Western blot analysis performed with respective membrane fractions using antibodies reacting against individual Gi proteins did not reveal any significant variation in the level of the 3 Gi proteins present in human osteoblast prior immunoprecipitation (data not shown).
Discussion
At present, there is no widely accepted model for the AIS pathogenesis. Nonetheless, the hypothesis of melatonin deficiency attracted much attention, mainly due to the striking similarities in the spine deformation generated in pinealectomized animal models. However, the role of melatonin remains highly controversial due to the accumulation of conflicting reports originating from studies on patients with AIS or animal models. These considerations led us to look beyond the melatonin deficiency hypothesis to investigate whether melatonin signal transduction is impaired in AIS. Indeed, it is conceivable that any mutation interfering with the normal signal transduction of melatonin could induce a scoliosis like a melatonin deficiency. Taking into account these considerations, we have demonstrated that the osteoblasts from patients with AIS showed hardly any capability to inhibit forskolin-stimulated adenylyl cyclase activity in response to melatonin, clearly indicating an impairment of melatonin signaling in AIS. Determination of cAMP inhibitory curves in presence of melatonin allowed a functional classification of patients with AIS into 3 groups based on their responsiveness toward melatonin signal ( Figure 2 and Table 3 ). Comparison of patients with AIS to those with congenital scoliosis showed no significant variation in those assays, suggesting a possible link between AIS and some type of congenital scoliosis. This observation is further supported by the work of Purkiss et al, who reported a high rate of idiopathic scoliosis (17.3%) in families affected by congenital scoliosis. 35 The authors of Coimmunoprecipitation assays were performed with specific anti-MT2 antibodies using purified membrane fractions prepared from human MG-63 osteoblast culture (top panel) and osteoblast cultures from AIS patient (case 22, bottom panel) treated overnight in different conditions: lanes 1-5-9, untreated; lanes 2-6 -10, with melatonin; lanes 3-7-11, with Na 3 VO 4 , a tyrosine phosphatase inhibitor; and lanes 4 -8 -12, with genistein, a tyrosine kinase inhibitor. Immunoblots were revealed with specific antibodies reacting with individual Gi with the exception of anti-Gi 3 antibodies, which cross-react also with human Gi 1 proteins. Lanes 1-4 with anti-Gi 1 ; lanes 5-8 with anti-Gi 2 , and lanes 9 -12 with anti-Gi 3 . Lanes 13-15 correspond to purified recombinant Gi 1-3 proteins respectively and were used as control for antibody specificity. The 60 kDa and 43 kDa bands correspond to the phosphorylated (inactive) and unphosphorylated (active) forms of Gi proteins, respectively. Note the changes in the phosphorylation patterns occurring in Gi proteins from the patient with AIS, showing increased phosphorylation and distinct regulation by kinase and phosphatase inhibitors tested.
that study raised the possibility that one genetic defect can cause or predispose to the development of either a dysostosis (congenital scoliosis) or a dysplasia (idiopathic scoliosis) involving the spine. It cannot be ruled out that both disorders could be caused by 2 gene defects, 1 for AIS and 1 for congenital scoliosis, which could both interfere with the normal signal transduction of melatonin. In the case of AIS, the great phenotypic heterogeneity observed is most likely caused by more than 1 gene defect directly or indirectly interfering with melatonin signal transduction. Such an assumption is further supported experimentally by our functional assays demonstrating at least 3 types of response in cAMP assays with melatonin in patients with AIS tested and the fact that different loci of susceptibility have been already identified in humans. 6,9,36 -38 Taken together, these data strongly indicate that more than 1 gene is involved in AIS etiopathogenesis. Furthermore, the detection of a melatonin signaling dysfunction in osteoblasts isolated from patients with AIS strongly argue in favor of a cell autonomous defect involved in AIS rather than a consequence caused by that condition.
Mechanisms Underlying a Melatonin-Signaling Dysfunction in Adolescent Idiopathic Scoliosis
Melatonin receptors are unlikely involved in such dysfunction because experimentally, we did not observe any type of alteration in the distribution or function of both melatonin receptor. Furthermore, natural and engineered mutations in single or both melatonin receptors did not lead to the formation of a scoliosis in mice and hamsters. 39 Nonetheless, the quadripedal condition of those animals could prevent or reduce the formation of a spinal deformity caused by mutations in those receptors. 40 -43 The impaired capability to inhibit forskolinstimulated adenylyl cyclase activity even in presence of Gpp(NH)p, a nonhydrolysable GTP analogue, indicated that the apparent impairment of melatonin signaling could be caused by a reduced functionality of Gi proteins as evidenced at least for 50% of patients with AIS tested. It is well known that Gi protein activation by this nonhydrolysable GTP analogue inhibits the production of cAMP. [22] [23] [24] [25] [26] Therefore, a deficiency of the Gi proteinmediated inhibitory system could be the cause of the dysfunction in melatonin signal transduction in osteoblasts from patients with AIS ( Figure 4) . Considering the multiplicity of GTP-binding proteins present in osteoblasts, 44 it remains unlikely that one particular G-protein is involved in such defect. However, the use of that nonhydrolysable GTP analogue is of interest, owing to a preferential affinity of Gpp(NH)p towards Gi proteins in the range of concentrations used has been evidenced, 45, 46 and the fact that Gi proteins are commonly 10 times more abundant than Gs in a variety of cells and tissues. 44 It cannot be ruled out that changes in Gi proteins affinity for GTP and Gpp(NH)p could be also triggered by posttranslational modifications of Gi proteins involving serine residues phosphorylation. Phosphorylation of Gi proteins at their N-terminus is well known to block the formation of functional heterotrimers with G␤ and G␥ subunits, preventing the inhibition of adenylyl cyclase Figure 6 . Immunodetection of Gi proteins coupled to MT2 receptors in AIS. Coimmunoprecipitation assays were performed with specific anti-MT2 antibodies using purified membrane fractions prepared from human osteoblast cultures isolated from AIS patient (top, case 37; bottom, case 29) treated overnight in different conditions: lanes 1-6 -11, untreated; lanes 2-7-12, with melatonin; lanes 3-8 -13, with Na 3 VO 4 , a tyrosine phosphatase inhibitor; lanes 4 -9 -14, with genistein, a tyrosine kinase inhibitor; and lanes 5-10 -15, with herbimycin, another tyrosine kinase inhibitor. Immunoblots were revealed with specific antibodies reacting with individual Gi with the exception of anti-Gi 3 antibodies, which cross-react also with human Gi 1 proteins. Lanes 1-5 with anti-Gi 1 ; lanes 6 -10 with anti-Gi 2 , and lanes 11-15 with anti-Gi 3 . Lanes 16 -18 correspond to purified recombinant Gi 1-3 proteins, respectively, and were used as control for antibody specificity. The 60 kDa and 43 kDa bands correspond to the phosphorylated (inactive) and unphosphorylated (active) forms of Gi proteins respectively. Note that both patients with AIS show a predominant coupling with phosphorylated Gi proteins. Figure 7 . Detection of phosphoserine residues in phosphorylated Gi proteins. Coimmunoprecipitation assays were performed with specific anti-MT2 antibodies using purified membrane fractions prepared from human MG-63 osteoblast cultures and immunoblot was revealed with specific antibodies reacting with anti-Gi 1 antibodies (A). Then, the immunoblot performed with MG-63 (control osteoblasts) was stripped and reprobed with antibodies recognizing phosphoserine residues (B). Numbering corresponds to cell cultures conditions: 1) untreated; 2) with melatonin; 3) with Na 3 VO 4 , a tyrosine phosphatase inhibitor; and 4) with genistein, a tyrosine kinase inhibitor. Lane 5 in both panels corresponds to purified recombinant Gi 1 proteins used as control. Note that only the 60 kDa forms (lanes 1 and 3) were detected with antiphosphoserine antibodies, whereas addition of melatonin (lane 2) or genistein (lane 4), a tyrosine kinase inhibitor, abrogates the formation of phosphorylated Gi proteins.
activity either in presence of melatonin or Gpp(NH)p. 47 Interestingly, the detection of only phosphorylated forms of Gi proteins coupled to MT2 receptors further support the involvement of aberrant posttranslational modifications inactivating Gi protein function, as shown in osteoblasts isolated from 3 distinct patients with AIS ( Figures  5 and 6 ). Results obtained with tyrosine kinase inhibitors, genistein, or herbimycin suggested that increased phosphorylation of Gi proteins could be caused by the loss of function of a phosphatase that remains to be determined. It cannot be ruled out that activating mutations either in a tyrosine kinase or a downstream serine kinase could generate also a similar effect. Taken together, these results could provide a plausible mechanism whereby higher levels of cAMP were detected in osteoblasts isolated from patients with AIS. The accumulation of high levels of cAMP in osteoblasts is known to suppress osteoblastic function through proteolytic degradation of Cbfa1, a key transcription factor essential for the formation of bone. We began our analysis of melatonin signaling with osteoblasts not only because bone tissue is well known to respond to melatonin in vitro and in vivo, [27] [28] [29] but also because the persistent osteopenia often observed in patients with AIS and in pinealectomized animals suggested that bone tissue is particularly affected in AIS. 21, 30, 32, 33 More recently, the histomorphometric data of Cheng et al on iliac crest biopsies and vertebrae of scoliotic patients showed that the osteoblasts and osteoclasts, the 2 bone-forming cell types, are impaired in their differentiation and/or functions in patients with AIS. 31 However, it is unlikely that bone is the only tissue affected in patients with AIS because melatonin-signaling activities have been demonstrated in many tissues and systems. Preliminary data obtained by similar assays with skeletal myoblasts, isolated from the same pool of patients and control patients, revealed that melatonin signaling is also impaired in muscle cells from patients with AIS (Moreau et al, unpublished data). In that perspective, it will be important to assess the contribution of each individual tissue and system where this neuro-hormone exerts its function to determine whether or not AIS pathogenesis is triggered by a systemic defect in melatonin signaling and the causes of such dysfunction.
Key Points
• Experimental data showed a melatonin signaling dysfunction in osteoblasts isolated from 100% of the patients with AIS tested.
• Classification of patients with AIS into 3 distinct groups suggested the presence of different mutations that could cause such dysfunction.
• Among possible causes, abnormalities in Gi proteins function could be involved in AIS pathogenesis.
